Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KMDA 
Kamada (KMDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KMDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.39% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 385.86M USD | Price to earnings Ratio 26.84 | 1Y Target Price 14.4 |
Price to earnings Ratio 26.84 | 1Y Target Price 14.4 | ||
Volume (30-day avg) 149895 | Beta 0.21 | 52 Weeks Range 4.61 - 8.90 | Updated Date 04/2/2025 |
52 Weeks Range 4.61 - 8.90 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 3.00% | Basic EPS (TTM) 0.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-04 | When Before Market | Estimate 0.0533 | Actual 0.07 |
Profitability
Profit Margin 8.98% | Operating Margin (TTM) 13.02% |
Management Effectiveness
Return on Assets (TTM) 3.45% | Return on Equity (TTM) 5.75% |
Valuation
Trailing PE 26.84 | Forward PE 24.57 | Enterprise Value 319404386 | Price to Sales(TTM) 2.4 |
Enterprise Value 319404386 | Price to Sales(TTM) 2.4 | ||
Enterprise Value to Revenue 1.98 | Enterprise Value to EBITDA 11.49 | Shares Outstanding 57505000 | Shares Floating 9184704 |
Shares Outstanding 57505000 | Shares Floating 9184704 | ||
Percent Insiders 7.22 | Percent Institutions 49.97 |
Analyst Ratings
Rating 4.5 | Target Price 14.25 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kamada
Company Overview
History and Background
Kamada was founded in 1990 and is headquartered in Israel. It is a biopharmaceutical company focused on plasma-derived protein therapeutics. It has expanded internationally and focused on developing and marketing specialized treatments.
Core Business Areas
- Plasma-Derived Protein Therapeutics: Develops, manufactures, and markets plasma-derived protein therapies, primarily focusing on Alpha-1 Antitrypsin Deficiency (AATD) and rabies.
- Proprietary Products: Focuses on development and commercialization of proprietary products utilizing Kamada's technology platform.
- Contract Manufacturing: Provides contract manufacturing services to other pharmaceutical companies.
Leadership and Structure
Kamada is led by a management team with experience in the pharmaceutical industry. The organizational structure includes departments for R&D, manufacturing, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Glassia: A plasma-derived Alpha-1 Antitrypsin (AAT) proteinase inhibitor indicated for chronic augmentation and maintenance therapy in adults with AAT deficiency. Market share is competitive but with a significant position in the AATD market. Competitors include CSL Behring (Prolastin), Grifols (Zemaira). Revenue not publicly broken out.
- KamRab: A rabies immune globulin (Human) indicated for post-exposure prophylaxis against rabies infection. Competitors include Grifols (HyperRab S/D). Revenue not publicly broken out.
- Varizig: A Varicella Zoster Immune Globulin (Human) indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk individuals. Competitors include Sanofi (Varitect). Revenue not publicly broken out.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth due to increased demand for specialized treatments and advancements in biotechnology. Competition is high, with significant R&D investments and regulatory hurdles.
Positioning
Kamada is a specialty biopharmaceutical company focused on niche markets with plasma-derived therapies. Its competitive advantages include its proprietary technology platform and manufacturing expertise.
Total Addressable Market (TAM)
The total market for plasma-derived protein therapeutics is estimated to be in the billions of dollars globally, and AATD and rabies treatments are specific segments within that. Kamada holds a significant position, especially in the AATD segment.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Proprietary technology platform
- Experienced management team
- Established manufacturing capabilities
- Global distribution network
Weaknesses
- Reliance on a limited number of products
- Competition from larger pharmaceutical companies
- Dependence on plasma supply
- Potential regulatory challenges
- Relatively small market capitalization
Opportunities
- Expansion into new markets
- Development of new products
- Strategic partnerships and acquisitions
- Increased demand for plasma-derived therapies
- Advancements in biotechnology
Threats
- Competition from biosimilars
- Changes in regulatory environment
- Fluctuations in plasma supply
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- Grifols (GRFS)
- Takeda (TAK)
Competitive Landscape
Kamada competes with larger pharmaceutical companies in the plasma-derived protein therapeutics market. Its competitive advantages include its specialized product portfolio and proprietary technology.
Major Acquisitions
Prometic Biotherapeutics Inc.
- Year: 2021
- Acquisition Price (USD millions): 45
- Strategic Rationale: Expanded product pipeline and manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Kamada has experienced growth through product sales and strategic initiatives.
Future Projections: Analyst estimates vary. Consult financial data providers for current projections.
Recent Initiatives: Recent initiatives may include product development, market expansion, and partnerships.
Summary
Kamada is a specialty biopharmaceutical company with a focus on plasma-derived protein therapeutics, particularly in niche markets like AAT deficiency. While it has proprietary technologies and a global distribution network, it faces competition from larger companies and relies on a limited product portfolio. Expanding into new markets and developing new products are key to future growth. The company needs to manage plasma supply effectively and watch for regulatory changes.
Similar Companies
GRFS
Grifols SA ADR
GRFS
Grifols SA ADR
HAE
Haemonetics Corporation
HAE
Haemonetics Corporation
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Providers
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional. Market share data is based on available estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kamada
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-05-31 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 420 | Website https://www.kamada.com |
Full time employees 420 | Website https://www.kamada.com | ||
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.